dutch strength


Great science is our backbone

Biotech companies thrive on access to excellent science, and the Netherlands offers this solid scientific backbone. Within a 120-mile radius, the Netherlands is home to eight leading University Medical Centers and twelve Universities engaged in biomedical research. Thanks to our bright and entrepreneurial scientists, the Netherlands holds a steady top position in publication productivity, citation indexes and number of patent applications.

The impressive Dutch contribution to the world’s medical science go way back. Some masters from back in the day include: Antoni van Leeuwenhoek (the first microbiologist), Herman Boerhaave (the founder of clinical teaching) and Willem Kolff who developed and applied the first functioning artificial kidney.

Hans Schikan, former CEO of Prosensa, SME Member of Top Team LSH: “In the Netherlands hundreds of thousands of passionate people are spending their days, their careers on helping patients to live normal lives. By continuous innovation in new treatment paradigms, novel medicines and diagnostics, and new interventions. And it is paying off.”

Today, the Netherlands is still a major player in the global Life Sciences & Health industry, with a strong technological position in molecular imaging, medical informatics, biopharmaceuticals, human and veterinary vaccines, regenerative medicine and biomaterials, medical technology and health infrastructure.

The Dutch sector owes this position to collaboration, cooperation and coalition building between bright minds, linking research to product and business creation. And, not to forget, due to our top-notch universities: all 13 Dutch universities are in the top 200 of global rankings.

Meet today’s masters
Prof. Hans Clevers ~ The first who identified stem cells in the intestine and one of the world's leading researchers on normal stem cells and their potential for regenerative therapy.

Prof. Ab Osterhaus ~ Leading authority in the field of virology. Osterhaus identified around 20 new viruses, including the coronavirus, stopping the emerging SARS outbreak.

Prof. Niels Geijsen ~ Pioneer of the method for the in vitro generation of germ cells from embryonic stem cells.

Prof. Jaap Goudsmit ~ One of the most important HIV-researchers in the 90s and influenza expert. He was among the first who discovered that the amount of HIV in blood predicted the progression to clinically manifest AIDS. Furthermore, Goudsmit discovered the achillesheel of the influenza virus that opened the way towards a universal influenza vaccine.

and many more…

Deciphering cellular proteins and pathways involved in virus replication and in suspension growth of Vero cells

The aim of this project is to make the production of viral vaccines less expensive. To achieve this, Intravacc aims at the identification of cellular pathways that are important in virus replication and suspension growth in Vero cells. By permanent modification of the identified host factors, Vero cell lines can be constructed that are better suited for the production of viral vaccines. The industrial partner, Applikon, is aiming at developing disposable, single use bioreactors, which offer flexibility and require less investment in infrastructure compared to conventional bioreactors. Combining these strategies in this partnership will ultimately result in the development of vaccines in less time at lower costs.

This innovative project will lead to more fundamental knowledge on proteins and intracellular pathways important for viral replication by doing siRNA screens. This knowledge will be used to develop new Vero cell lines with modulated host genes using CRISPR-CAS9 that can significantly enhance virus production at reduced costs, thereby promoting global introduction of affordable vaccines. Also, we aim to use the knowledge obtained from the screens to design Vero cells that are capable of growing in suspension, which is a great advantage for easier scale-up and less expensive production of vaccines. The last aim is  to develop single-use, disposable bioreactors, that will eliminate the costs in the vaccine production process associated with disassembly, cleaning and reassembly of conventional bioreactors. This offers flexibility in vaccine development, and in change-over from one vaccine manufacturing process to another. In the last phase of this project, the modified Vero cells will be cultured at lab-scale in the disposable bioreactors developed by Applikon.

'Sticky' peptides to fight antimicrobial resistance

PharmAMPs: Pharmaceutical development of antimicrobial peptides for the prevention and treatment of infections against (multi)-drug resistant bacteria.

The concept of using AMPs for therapeutic purposes has been around for some time. Unfortunately, the 1st generation AMPs had limitations that prevented further development, especially with regard to their (limited) potency and high cost of goods, resulting in poor commercial perspectives. Several peptides have been tested in clinical studies against a range of topical infections, but their development was halted for these reasons.

A new public private partnership was formed between the Leiden University Medical Centre (LUMC) and Madam Therapeutics with the intent to work on 2nd generation peptides with improved characteristics. Madam Therapeutics, is a near clinical stage biotech company that is developing a new generation of AMPs specifically to combat resistant bacterial infections and to prevent and treat infections that are currently left untreated due to the risk of resistance development with current antibiotics. The new peptides are based on technology from LUMC with whom Madam Therapeutics has been working closely over the recent years to develop the most optimal peptides, which we are now converting into powerful antibacterial products.

Within this PPP, we have established that the lead peptide (SAAP-148) indeed has significant advantages over traditional antibiotics. SAAP-148 was found to be a very effective, broad-spectrum anti-microbial peptide which possesses very rapid bactericidal activity. SAAP-148 has shown in this project to be very effective against bacteria residing in biofilms whereas traditional antibiotics are not. SAAP-148 is also very effective in the killing of (multi-) resistant bacteria and is very robust against resistance formation itself. Finally, we established that SAAP-148 has also shown significantly more potency than 1st generation AMPs in in-vitro comparison studies; in fact we demonstrated that SAAP-148 is one of the first in its class to be active at a sub-micromolar range.

As a follow-up to this project, Madam Therapeutics and LUMC are now preparing the first clinical proof of concept studies with the lead product SAAP-148 formulated as a gel for topical treatment of bacterial infections in chronic wounds, burns and in a nose gel to treat nasal MRSA carriers. In addition, we are also investing possible novel PPPs for collaborative (academic) research efforts and continuous pre-clinical development of other AMP-based products for other indications and other formulations.